CONNEQT Expands U.S. Trial Contract By 33% To About $1 Million
CQT: $0.005 +25.00% · MC: $5M
CONNEQT Health has expanded its U.S. Phase 2b clinical trial contract by 33%, adding approximately US$0.24 million and lifting total contract value to approximately US$0.95 million. The amendment expands the trial from 30 to 45 sites, with revenue to be recognised over the trial period.

Comments